The CSS, initially introduced by Cristofanilli et al., detects epithelial cell adhesion molecule (EpCAM)-positive CTC in peripheral blood and has demonstrated an impact on risk stratification and disease management in breast cancer and other malignancies [15, 16]. This evidence concerns the gene EPCAM and breast carcinoma.